Close Menu

NEW YORK – Interpace Diagnostics announced after the close of the market on Monday that it has bought assets and certain liabilities constituting the biopharma services business of Cancer Genetics for about $23.5 million.

At the closing of the deal, Interpace paid Cancer Genetics $13.8 million in cash. It also issued Cancer Genetics a $7.7 million, 6 percent interest bearing note due upon the earlier of Interpace's shareholder approval and second tranche investments by private equity firm Ampersand Capital Partners, or three years.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.